Established in 2019, PsiVac is a privately-owned UK Biotechnology Research and Development company focused on the development of new therapeutic cancer treatment.
The company uses an oncolytic Adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumour cells for the treatment of cancer.